Reviewer’s report

Title: Preclinical evaluation of Sunitinib as a single agent in the prophylactic setting in a mouse model of bone metastases.

Version: 1 Date: 25 August 2012

Reviewer: Daniel Keizman

Reviewer’s report:

The manuscript is well written.

Minor comments: The authors should discuss study limitations
1. whether their findings are specific to sunitinib or generalizable to other tyrosine kinase or MTOR inhibitors is not known.
2. whether the combination of sunitinib and an osteoclast inhibitor (bisphosphonates or denosumab) would lead to different results is not known
3. Ongoing adjuvant clinical trials, for example pazopanib versus placebo in high risk RCC may give some clinical input regarding prevention of bone metastases in diseases other than breast cancer

Level of interest: An article of importance in its field

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.